Provided is a compound preparation which comprises at least one selected from the group consisting of ω3 polyvalent unsaturated fatty acids and pharmaceutically acceptable salts and esters thereof, and comprises at least one selected from the group consisting of statin compounds and pharmaceutically acceptable salts thereof. The compound preparation has a capsule film pH of 7.0 to 9.5 and is in the form of a soft capsule. The compound preparation inhibits decomposition of the statin compounds and/or degeneration/insolubilization of the capsule film. A medical use for the compound preparation, a method for producing the compound preparation, and a method for using the compound preparation are also provided.
